New Educational Leaflet on SIDs is Out!

Discover IPOPI’s newest leaflet on Secondary Immunodeficiencies (SIDs). Designed for patients, caregivers, and healthcare professionals, this educational tool aims to increase understanding of SIDs — an often under-recognised area of immune health.

Through clear explanations and practical guidance, the leaflet educates readers on what SIDs are, the challenges of diagnosing and managing SIDs, and their connection to Primary Immunodeficiencies (PIDs).

Learn more today and help us spread knowledge about SIDs.

A special thanks to Grifols for supporting the production of this important resource.

 

/by

Thank You and See You in Mallorca!

We extend our heartfelt thanks to everyone who made IPIC2025 an unforgettable success!

With over 900 attendees, IPIC2025 was a truly inspiring gathering of our global community—filled with learning, collaboration, and shared commitment to advancing care for people with primary immunodeficiencies.

As we close this remarkable chapter, we are already looking ahead with excitement to our next congress: IPIC2027, taking place in beautiful Mallorca, Spain, from November 3–5, 2027.

In 2027, our congress will elevate primary immunodeficiency care as we learn, connect, and make lasting memories on the vibrant island of Mallorca.

Thank you once again for your continued support and engagement. We can’t wait to welcome you to Mallorca in 2027 for what promises to be another milestone event for the PI community. Until then, stay connected—and keep the spirit of collaboration alive!

🎥 Relive the highlights of IPIC2025 by watching our recap video here.

📸 View the IPIC2025 photo gallery here.

 

/by

IPOPI Applauds EMA’s Positive Opinion on Waskyra™ for Wiskott-Aldrich Syndrome

IPOPI has welcomed the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The opinion recommends granting marketing authorisation in the European Union for Waskyra™, a groundbreaking ex vivo gene therapy for Wiskott-Aldrich Syndrome (WAS), a rare and life-threatening primary immunodeficiency.

“This marks a significant milestone for gene therapy in the European Union, offering new hope for patients with Wiskott-Aldrich Syndrome,” said Johan Prévot, Executive Director of IPOPI and Board Member of the AGORA Foundation. “This positive opinion will not only increase access to life-saving therapies for those affected by WAS but could also pave the way for the development of more innovative treatments for other primary immunodeficiencies and rare disorders,” added Martine Pergent, IPOPI President. For more information, see here.

 

/by